Quest Diagnostics’s Underperform Rating Reaffirmed at Zacks (DGX)
Quest Diagnostics (NYSE:DGX)‘s stock had its “underperform” rating reaffirmed by Zacks in a research report issued on Tuesday, ARN reports. They currently have a $49.00 target price on the stock. Zacks‘ target price points to a potential downside of 8.85% from the stock’s previous close.
Zacks‘ analyst wrote, “Quest Diagnostics reported a dismal third quarter 2013 with adjusted EPS of $1.02, lagging the Zacks Consensus Estimate by $0.02 and the year-ago earnings by 11.3%. Besides, revenues of $1.79 billion were down 1.9%, also failing to meet the Zacks Consensus Estimate. The current market environment continues to pose challenges in the form of lower health care utilization and Medicare cuts. We are also concerned with the overall soft industry trends leading to volume pressure as reflected in the conservative 2013 outlook. Although, we are positive on the company’s organizational restructuring initiative and the strategy to align assets in core diagnostics information service business, near-term visibility remains a matter of concern. Accordingly, we reiterate the stock at Underperform. “
DGX has been the subject of a number of other recent research reports. Analysts at Maxim Group initiated coverage on shares of Quest Diagnostics in a research note to investors on Tuesday. They set a “buy” rating and a $68.00 price target on the stock. Separately, analysts at FBR Capital Markets cut their price target on shares of Quest Diagnostics from $68.00 to $60.00 in a research note to investors on Monday. They now have a “market perform” rating on the stock. Finally, analysts at JMP Securities initiated coverage on shares of Quest Diagnostics in a research note to investors on Wednesday, December 18th. They set a “market perform” rating on the stock. Five research analysts have rated the stock with a sell rating, fifteen have given a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $58.89.
Shares of Quest Diagnostics (NYSE:DGX) traded down 1.00% on Tuesday, hitting $53.225. 2,477,808 shares of the company’s stock traded hands. Quest Diagnostics has a 52-week low of $51.90 and a 52-week high of $64.10. The stock’s 50-day moving average is $54.21 and its 200-day moving average is $58.84. The company has a market cap of $7.740 billion and a P/E ratio of 11.03.
Quest Diagnostics Incorporated (NYSE:DGX)is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.